GSK25
| Code | Size | Price |
|---|
| SYN-1124-M100 | 100 mg | Enquire |
Quantity:
| SYN-1124-M050 | 50 mg | Enquire |
Quantity:
| SYN-1124-M001 | 1 mg | £233.00 |
Quantity:
| SYN-1124-M005 | 5 mg | £461.00 |
Quantity:
| SYN-1124-M010 | 10 mg | £719.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
GSK-25
Appearance:
Solid.
CAS:
874119-56-9
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C24H16Cl2F2N6O/c1-11-21(24(35)32-19-6-13-10-30-34-18(13)9-17(19)28)22(15-3-2-14(25)8-16(15)27)33-23(31-11)12-4-5-29-20(26)7-12/h2-10,22H,1H3,(H,30,34)(H,31,33)(H,32,35)
InChiKey:
KZYAHEIPPAPADQ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 874119-56-9. Formula: C24H16Cl2F2N6O. MW: 513.3. GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC(50) of 398nM, p70S6K IC(50) of 1000nM), and a dramatically improved P450 profile (>2.2µM at all isozymes tested).
Molecular Formula:
C24H16Cl2F2N6O
Molecular Weight:
513.3
Package Type:
Plastic Vial
Product Description:
GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC(50) of 398nM, p70S6K IC(50) of 1000nM), and a dramatically improved P450 profile (>2.2µM at all isozymes tested).
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases: C.A. Sehon, et al.; J. Med. Chem. 51, 6631 (2008)
Related Products
| Product Name | Product Code | Supplier | AICAR | AG-CR1-0061 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|